BluGlass (ASX:BLG) ships prototype products
21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.
21Jun
16Jun
Knosys (ASX:KNO) – providing SaaS solutions for information management
16 Jun 2022 - Knosys Limited (ASX:KNO) Managing Director John Thompson provides an update on the company, discussing demand drivers, recurring revenue and growth strategy.
09Jun
Novatti Group (ASX:NOV) announces stablecoin deals with Stellar and Ripple
09 Jun 2022 - Novatti Group Limited (ASX:NOV) CEO and Managing Director Peter Cook discusses Novatti's recent deals with Ripple and Stellar.
02Jun
BluGlass (ASX:BLG) expanding in California
02 Jun 2022 - BluGlass Limited (ASX:BLG) Executive Chair James Walker provides an update on the company, discussing new staff and developments at BluGlass' manufacturing facility in Silicon Valley.
30May
Should an investor allocate to cryptocurrencies like Bitcoin and Ethereum?
30 May 2022 - Fred Pye, CEO and Chairman of digital asset manager 3iQ, discusses the future of cryptocurrencies and the launch of two crypto ETFs in Australia based on Ethereum and Bitcoin.
27May
TerraCom (ASX:TER) – From debt to dividends
27 May 2022 - TerraCom Limited (ASX:TER) Executive Chairman Craig Ransley discusses drivers behind the company's performance and share price over the previous year.
25May
Market update with Shaw and Partners, May 2022
25 May 2022 - Shaw and Partners Chief Investment Officer Martin Crabb discusses the paradox of rising valuations in a looming bear market.
18May
Radiopharm Theranostics (ASX:RAD) – developing a portfolio of assets targeting cancer
18 May 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's pipeline and discusses the recent licensing of an asset from UCLA.
18May
Chimeric Therapeutics (ASX:CHM) expands cancer trials
18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
17May
PropTech Group (ASX:PTG) discusses Q3 FY22 results
17 May 2022 - PropTech Group Limited (ASX:PTG) Managing Director and Group CEO Joe Hanna discusses drivers behind PropTech's results, providing an update on the company's growth strategies.